Seres Therapeutics, Inc (MCRB)

Etorro trading 970x250
Seres Therapeutics, Inc (MCRB) Logo

About Seres Therapeutics, Inc

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company’s lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb clinical trial to treat ulcerative colitis; SER-401, which is in Phase Ib clinical trial for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical trial for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262 to treat an initial recurrence of CDI; and SER-155, a cultivated bacteria microbiome drug designed to prevent mortality due to gastrointestinal infections, bacteremia, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Address: 200 Sidney Street, Cambridge, MA, United States, 02139

Seres Therapeutics, Inc News and around…

Latest news about Seres Therapeutics, Inc (MCRB) common stock and company :

Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
23 May, 2022 Yahoo! Finance

Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Venture Partner at Flagship Pioneering, as well as the former President, CEO, and Chairman of the Board of Seres Therapeutics Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinic

Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
22 May, 2022 FinancialContent

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome company, today announced the presentation of data from its Phase 3 ECOSPOR III study that suggest investigational microbiome-based therapeutic SER-109 prevents recurrent C. difficile infections (rCDI) by rapidly establishing a long-lasting colony of beneficial gut microbes, which can produce fatty acids that disrupt the C. difficile lifecycle. These data were shared in oral and poster presentations at the 2022 Digestive Disease Week (DDW) Annual Meeting.

Seres Therapeutics Earnings Perspective: Return On Capital Employed
19 May, 2022 FinancialContent

Benzinga Pro data, Seres Therapeutics (NASDAQ:MCRB) reported Q1 sales of $1.49 million. Earnings fell to a loss of $56.62 million, ...

Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
10 May, 2022 FinancialContent

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present data from its ECOSPOR III trial of SER-109 at the Digestive Disease Week® (DDW) Annual Meeting, which is taking place May 21-24, 2022. SER-109 is an investigational oral microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI). With an oral and poster presentation, Seres will present data on how SER-109 restores the functionality of the microbiome in a rapid and durable manner, which further supports the potential of microbiome therapeutics. Seres expects to finalize a Biologics License Application (BLA) submission for SER-109 with the U.S. Food and Drug Administration (FDA) in mid-2022.

Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Slashed This Year's Revenue Estimates By 59%
05 May, 2022 Yahoo! Finance

Market forces rained on the parade of Seres Therapeutics, Inc. ( NASDAQ:MCRB ) shareholders today, when the analysts...

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
04 May, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kezar Life's Lead Asset ...

Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
04 May, 2022 Yahoo! Finance

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.93% and 79.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Recap: Seres Therapeutics Q1 Earnings
04 May, 2022 FinancialContent

Seres Therapeutics (NASDAQ:MCRB) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what ...

Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
04 May, 2022 FinancialContent

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2022 financial results and provided business updates.

Preview: Seres Therapeutics's Earnings
03 May, 2022 FinancialContent

Seres Therapeutics (NASDAQ:MCRB) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors ...

How To Attend Seres Therapeutics Q1 2022 Earnings Conference Call
29 Apr, 2022 FinancialContent

Seres Therapeutics (NASDAQ:MCRB) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. How to ...

Seres Therapeutics to Host First Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2022
28 Apr, 2022 FinancialContent

Seres Therapeutics, Inc. (NASDAQ: MCRB) a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 4, 2022 at 8:30 a.m. ET to discuss first quarter 2022 results and provide a general business update.

Stocks That Hit 52-Week Lows On Thursday
21 Apr, 2022 FinancialContent

On Thursday, 236 companies hit new 52-week lows. Intriguing Points From Today's 52-Week ...

12 Health Care Stocks Moving In Wednesday's After-Market Session
20 Apr, 2022 FinancialContent

Gainers Endo International (NASDAQ:ENDP) stock rose 7.3% to $2.78 during Wednesday's after-market session. Today's trading volume for ...

Analysts See 104% Gains Ahead For The Holdings of XBI
12 Apr, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $177.86 per unit.

Seres Therapeutics Ditches Its SER-301 Phase 1b Second Study In Ulcerative Colitis
07 Apr, 2022 FinancialContent

In its SEC filing,Seres Therapeutics Inc(NASDAQ:MCRB) disclosed it would not move forward with the planned SER-301 ...

The Biotech Sector Nears an Inflection Point; Analysts Offer 3 Stocks to Consider
22 Mar, 2022 Yahoo! Finance

Mirroring the markets’ overall trend, the biotech sector has not gotten off to a good start in 2022, as evidenced by the Nasdaq Biotechnology Index (NBI) tilting 12% into the red year-to-date. However, according to Yaron Werber, biotech analyst at investment firm Cowen, that is not necessarily indicative of how the rest of the year will pan out. In fact, taking the Cowen Annual Health Care Conference in late February/early March (this year’s took place between March 7-9) as a “time point” that c

Seres Therapeutics' SER-155 Reduces Infection, GvHD In Animal Study
18 Mar, 2022 FinancialContent

Seres Therapeutics Inc(NASDAQ: MCRB) will present preclinical findings at the European Bone Marrow Transplantation (EBMT) Annual ...

Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting
18 Mar, 2022 FinancialContent

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, will present preclinical findings tomorrow at the European Bone Marrow Transplantation (EBMT) Annual Meeting that suggest SER-155 works by targeting the host immune response, potentially allowing patients undergoing hematopoietic stem cell transplantation (HSCT) to avoid infection or Graft-versus-Host Disease (GvHD), which currently afflict about half of this patient population. SER-155 is being evaluated in an ongoing Phase 1b clinical trial.

Seres Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference
10 Mar, 2022 FinancialContent

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will present at the 32nd Annual Oppenheimer Healthcare Conference on Thursday, March 17, 2022 at 8:00 a.m. ET.

Implied XBI Analyst Target Price: $190
04 Mar, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $189.63 per unit.

Seres Therapeutics to Participate in Cowen 42nd Annual Health Care Conference
03 Mar, 2022 FinancialContent

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 10:30 a.m. ET.

Seres Therapeutics (MCRB) Reports Q4 Loss, Lags Revenue Estimates
01 Mar, 2022 Yahoo! Finance

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -22.22% and 62.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics: Q4 Earnings Insights
01 Mar, 2022 FinancialContent

Seres Therapeutics (NASDAQ:MCRB) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what ...

Seres Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
01 Mar, 2022 FinancialContent

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2021 financial results and provided business updates.

Earnings Scheduled For March 1, 2022
01 Mar, 2022 FinancialContent

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth ...

Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Lags Revenue Estimates
28 Feb, 2022 Yahoo! Finance

Acadia (ACAD) delivered earnings and revenue surprises of -12.50% and 3.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Seres Therapeutics
28 Feb, 2022 FinancialContent

Seres Therapeutics (NASDAQ:MCRB) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need ...

Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs
28 Feb, 2022 Yahoo! Finance

Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to ad

Seres Therapeutics to Present at Chardan Metagenomics and Microbiome Medicines Summit
22 Feb, 2022 FinancialContent

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will present at the Chardan Metagenomics and Microbiome Medicines Summit on Tuesday, March 1, 2022 at 2:00 p.m. ET.

Seres Therapeutics, Inc (MCRB) is a NASDAQ Common Stock listed in , ,

970x250